Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Sep 30, 2015 at 12:55 PM EDT

Civitas Readies for Secondary Offering

Selling stockholders are offering 3 million Civitas Solutions shares in a secondary offering valued up to more than $84 million.

Lee Jackson | Sep 30, 2015 at 9:10 AM EDT

2 Deutsche Bank Health Care Focus Stocks Have Big Upside Potential

A new report from Deutsche Bank makes the case that the selling in health care stocks is way overdone, and…

Trey Thoelcke | Sep 30, 2015 at 7:35 AM EDT

DaVita Eyes Expansion Into Brazil

DaVita HealthCare Partners announced that it will be expanding its footprint in emerging markets by beginning operations in Brazil.

Chris Lange | Sep 29, 2015 at 4:09 PM EDT

Ceres Scores With Licensing Agreement

Ceres announced that KWS SAAT SE, a global seed developer with operations in over 70 counties, will evaluate its Persephone…

Chris Lange | Sep 29, 2015 at 1:20 PM EDT

CytomX Therapeutics Sets Terms for IPO

More than 6 million CytomX shares are expected to price in the range of $14 to $16 in an IPO…

Chris Lange | Sep 29, 2015 at 1:10 PM EDT

Why Oppenheimer Sees Community Health Worth Almost Twice as Much

Despite a declining health care sector of late, one key analyst sees potential in Community Health Systems.

Chris Lange | Sep 29, 2015 at 11:45 AM EDT

Key Analyst Sees Opportunity in Diagnostics Sell-Off

The unexpected reimbursement rate proposals by the Center for Medicaid hit the diagnostic sector on Monday.

Jon C. Ogg | Sep 29, 2015 at 11:25 AM EDT

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it…

Chris Lange | Sep 29, 2015 at 9:55 AM EDT

Novavax Rekindles Positive Momentum With RSV and Gates Grant

Novavax has announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate…

Chris Lange | Sep 29, 2015 at 9:05 AM EDT

Esperion Update Not Enough for Investors

Esperion plans to conduct multiple Phase 3 clinical trials that will separately evaluate patients with statin intolerance.

Chris Lange | Sep 28, 2015 at 12:10 PM EDT

Why Argus Thinks Now Is the Time to Buy Vertex

Argus has been waiting for a better valuation to upgrade Vertex Pharmaceuticals, and the recent weakness in the stock price…

Chris Lange | Sep 28, 2015 at 8:55 AM EDT

Verastem Falls on Halted Phase 2 Enrollment

Verastem has announced that it has stopped enrollment in its Phase 2 study of VS-6063 for patients with mesothelioma.

Chris Lange | Sep 26, 2015 at 9:25 AM EDT

How the Top Biotechs Handled the Valuation Shock

24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a…

Lee Jackson | Sep 25, 2015 at 9:50 AM EDT

3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness

In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.

Chris Lange | Sep 25, 2015 at 8:40 AM EDT

Short Sellers Boost Positions in Major Pharma

The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

1 … 242 243 244 245 246 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Civitas Readies for Secondary Offering

2 Deutsche Bank Health Care Focus Stocks Have Big Upside Potential

DaVita Eyes Expansion Into Brazil

Ceres Scores With Licensing Agreement

CytomX Therapeutics Sets Terms for IPO

Why Oppenheimer Sees Community Health Worth Almost Twice as Much

Key Analyst Sees Opportunity in Diagnostics Sell-Off

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

Novavax Rekindles Positive Momentum With RSV and Gates Grant

Esperion Update Not Enough for Investors

Why Argus Thinks Now Is the Time to Buy Vertex

Verastem Falls on Halted Phase 2 Enrollment

How the Top Biotechs Handled the Valuation Shock

3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness

Short Sellers Boost Positions in Major Pharma

Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Live Nasdaq Composite: Market Rout Deepens as Inflation Hits Three-Year High and Oil Climbs

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

May CPI Surges to 4.2%, but the Fed May Not Be Ready to Raise Rates

Forget Intel Corporation: As June Volatility Rocks Chip Stocks, This Tech Monopoly Is The Smart Money Pivot

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

Can You Afford To Retire To Trump Tower? We Ran the Budget. It's a Lot.

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

May CPI Surges to 4.2%, but the Fed May Not Be Ready to Raise Rates

Health and Healthcare Articles

All Health and Healthcare Articles

Civitas Readies for Secondary Offering

2 Deutsche Bank Health Care Focus Stocks Have Big Upside Potential

DaVita Eyes Expansion Into Brazil

Ceres Scores With Licensing Agreement

CytomX Therapeutics Sets Terms for IPO

Why Oppenheimer Sees Community Health Worth Almost Twice as Much

Key Analyst Sees Opportunity in Diagnostics Sell-Off

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

Novavax Rekindles Positive Momentum With RSV and Gates Grant

Esperion Update Not Enough for Investors

Why Argus Thinks Now Is the Time to Buy Vertex

Verastem Falls on Halted Phase 2 Enrollment

How the Top Biotechs Handled the Valuation Shock

3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness

Short Sellers Boost Positions in Major Pharma

Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Live Nasdaq Composite: Market Rout Deepens as Inflation Hits Three-Year High and Oil Climbs

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

May CPI Surges to 4.2%, but the Fed May Not Be Ready to Raise Rates

Forget Intel Corporation: As June Volatility Rocks Chip Stocks, This Tech Monopoly Is The Smart Money Pivot

Featured Reads

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

Can You Afford To Retire To Trump Tower? We Ran the Budget. It's a Lot.